VIVUS Shares Progress on Pipeline and Key Program Milestones
Digest more
Opinion
3dOpinion
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be heard in its attempt to gain approval for the drug ...
Sanofi is set to pay Lexicon Pharmaceuticals $260 million (€236 million) to get out of a diabetes pact. The dissolution of the alliance follows the generation of mixed clinical data on Zynquista in Type 1 diabetics that failed to persuade the FDA to ...
Investors might want to bet on Lexicon Pharmaceuticals (LXRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating regulatory hurdles. Last year, Lexicon broke its losing streak ...
Every investor in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private equity firms with 48% ownership. That is, the group stands to benefit ...
Feedback